Loading... Please wait.
Company profile
Inventiva is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. The group is developing two drug candidates - lanifibranor and odiparcil - in non-alcoholic steatohepatitis (« NASH ») and mucopolysaccharidosis (« MPS ») respectively, as well as a portfolio of several programs in the preclinical stage. Lanifibranor, is currently in a pivotal Phase III clinical trial « NATiV3 » for the treatment of patients with MASH/NASH and Odiparcil is currently in Phase IIa for the treatment of type VI MPS. As part of Inventiva’s decision to focus clinical efforts on the development of Lanifibranor, it suspended clinical efforts relating to Odiparcil and is reviewing available options with respect to its potential further development.
Meanwhile, Inventiva is in the process of selecting an oncology drug candidate for the Hippo signaling pathway.
Source:
Cofisem
-
Last Update:
29 Mar 2025
Key Executives
| Chairman and Chief Executive Officer | Frédéric Cren | ||||
| Deputy CEO | Pierre Broqua | ||||
| Deputy General Manager | Jean Volatier | ||||
| Administrative & Finance Director | Jean Volatier | ||||
| Strategy Director | Pascaline Clerc | ||||
| General Counsel | Eric Duranson | ||||
| Chief Human Resources Officer | Nathalie Harroy | ||||
| Source: Cofisem - Last Update: 29 Mar 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 9.198 | 17.477 | 12.179 | 4.194 | 372 |
| Income from ordinary activities | 14.724 | 23.163 | 18.814 | 8.501 | 5.263 |
| Operating income | -97.558 | -102.709 | -57.110 | -52.114 | -29.719 |
| Cost of financial indebtedness net | 4.187 | 194 | 81 | -160 | |
| Equity-accounted companies contribution to income | -313 | -2.016 | 0 | ||
| Net profit from discontinued activities | |||||
| Net income | -184.212 | -110.426 | -54.274 | -49.635 | -33.619 |
| Net income (Group share) | -110.426 | -54.274 | -49.635 | -33.619 | |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Source: Cofisem - Last Update: 29 Mar 2025 | |||||
Shareholder information
Address
Inventiva
50 Rue de Dijon
FR-21121
Daix
France
Phone number:
+33 (0)3 80 44 75 00
Source:
Cofisem
-
Last Update:
29 Mar 2025
Contact
Source: Inventiva - Last Update: 29 Mar 2025